WillItSurvive
No grouping · acquisition pending · Malaysia

Medikra Inc.

Clinical-stage botanical obesity supplement maker seeking a US listing.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: IPO pricing or withdrawal decision on the F-1 filed January 20, 2026
The call

Medikra holds regulatory paperwork for a botanical extract but no revenue, no drug filing, and an IPO that has not priced.

Medikra makes plant-based weight-loss supplements and is trying to develop them into prescription drugs, but it has earned only $16,099 in revenue and lost $776,000 last year. It is very hard to compete because Novo Nordisk and Eli Lilly already sell GLP-1 drugs that help people lose 15 to 20 percent of their body weight, while Medikra's supplements sit in a weaker, less proven middle ground. The company's future hinges entirely on whether it can raise the $25 million it needs to run expensive drug trials and whether its stalled initial public offering actually closes before the end of 2026, since continued delays or a failed offering would likely mean the money runs out.

Why
01
AI pressure: None apparent. Medikra sells a plant extract, not software; no AI agent competes directly for its narrow supplement niche. Could AI do the core job? Unlikely.
02
Bigger players: Novo Nordisk and Eli Lilly GLP-1 drugs. Ozempic and Zepbound already deliver 15-20% weight loss, dwarfing a supplement with $16K in trailing revenue. Could a giant copy it? Probably.
03
What protects it. FDA NDI notices and EU Novel Food clearance let it keep selling SKF7 legally while it tries to become a drug.
What would change this call
Whether Medikra's IPO prices and lists on a US exchange before end of 2026. Confirms whether public markets have any confidence in the offering after a six-month stall.
Whether Medikra files an IND or CTA for SKF7 with FDA or another regulator. Shows whether it is actually pursuing a drug pathway or remains a supplement seller.
Whether Medikra reports any signed distribution or partnership deal with a nutraceutical or pharma company. Would indicate real commercial traction beyond its near-zero current revenue.
Key numbers
  • TTM revenue $16,099, down 61.7% year over year (2026-07-14)
  • IPO target upsized to $25M, 4.5M shares (2026-02-13)
  • IPO still unpriced six months after filing (2026-07-29)
Named risks
  • IPO stalled over six months post-filing as of July 2026, signaling weak demand or SEC review. Severity: high
  • Trailing revenue collapsed to $16,099, down 61.7% YoY, on a near-zero commercial base. Severity: high
  • No IND filed with FDA or CTA filed in EU for SKF7 as a drug as of February 2026. Severity: medium
  • $25M raise likely insufficient to fund Phase III trials needed for drug pathway ambitions. Severity: medium
  • Cap table and prior funding history largely undocumented and paywalled. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Novo Nordisk / Eli Lilly (GLP-1 drugs)losing toLilly's Zepbound claimed 15-20% weight loss vs Medikra's unlaunched botanical supplement, as of May 2025
Laila Nutraceuticals (Humerus3)contestingPeer-reviewed reviews list Humerus3 among botanical anti-obesity formulations alongside SKF7, as of Jul 2026
Generic botanical actives (green tea catechins, berberine, curcumin, resveratrol)contestingAcademic literature groups these with SKF7 as competing natural anti-obesity compounds, cited Jul 2026
Questions people ask
Is Medikra profitable in 2026?
No. Medikra reported trailing twelve month revenue of just $16,099, down 61.7% year over year, alongside a net loss of about $776,370, as of July 14, 2026. Operating margin sits near negative 5,400%, reflecting a pre-commercial botanical drug developer with no meaningful sales base.
Has Medikra's IPO actually priced yet?
Not as of July 23, 2026. Medikra filed its F-1 publicly on January 20, 2026 and upsized the deal to about $25 million on February 13, 2026, but the offering still had not priced or begun trading six months later, per stockanalysis.com tracking on July 23, 2026.
Could AI replace what Medikra does?
Unlikely directly. Medikra's value sits in completed Phase I/II clinical trial data across Malaysia, Indonesia and India, plus FDA NDI clearances from 2020 and 2022 and a 2023 EU Novel Food authorization, none of which are AI-replaceable regulatory or trial assets as of February 2026.
Who is Medikra's biggest competitor?
The dominant threat is GLP-1 obesity drugmakers Novo Nordisk and Eli Lilly, whose therapies like Zepbound deliver 15-20% weight loss per Lilly's own May 2025 SURMOUNT-5 results, dwarfing the efficacy positioning available to Medikra's botanical supplement SKF7, which targets a much narrower niche.
Is it risky to join Medikra as an employee?
Yes, structurally risky. As of January 2026 Medikra had only 10 employees, trailing revenue of $16,099, and a stalled IPO that still hadn't priced by July 29, 2026, six-plus months after filing, a combination signaling weak investor demand or ongoing SEC review.
Who owns Medikra Inc.?
Medikra is a Cayman Islands incorporated company operating through its Malaysian subsidiary Medika Natura Sdn. Bhd., founded in 2006. As of its January 2026 F-1 filing, no large institutional venture round is publicly documented; the company appears founder and grant backed ahead of its planned NYSE American listing under MDKR.
Timeline
  • 2026-07-23IPO still unpriced six months after filing; implied valuation $165-170M per stockanalysis.com
  • 2026-07-14TTM revenue reported at $16,099, down 61.7% YoY; net loss about $776,370
  • 2026-02-13F-1/A upsizes offering to ~4.5M shares, targeting ~$25M at midpoint
  • 2026-01-20Medikra files public F-1 with SEC, setting initial terms of ~$20M IPO
  • 2025-08-22Medikra files confidentially with SEC ahead of public F-1
  • 2023EU EFSA grants Novel Food authorization for SKF7 up to 350mg/day for adults
  • 2022FDA accepts New Dietary Ingredient notification for SKF7 at 750mg
  • 2020FDA accepts New Dietary Ingredient notification for SKF7 at 300mg
  • 2006Medika Natura Sdn. Bhd., Medikra's Malaysian operating subsidiary, is founded
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources